Therapeutic Targeting of microRNAs in Cancer: Future Perspectives

Drug Dev Res. 2015 Nov;76(7):382-8. doi: 10.1002/ddr.21273. Epub 2015 Aug 26.

Abstract

Preclinical Research The discovery of microRNAs (miRNAs) and their link with cancer has opened a new era in cancer therapeutics. Approximately, 18 - 24 nucleotides long, miRNAs can up-regulate or down-regulate gene expression in many cancer types and are respectively categorized as oncogenes (oncomirs) or tumor suppressors. Expression profiles of miRNAs with biomarker potential can be used for the classification, diagnosis, therapeutic treatment, and prognosis of different cancer types. miRNA mimics and miRNA antagonists are the two main approaches to miRNA-based cancer therapies that respectively inhibit oncomirs or restore the expression of tumor suppressive miRNAs. This review serves to provide some general insight into miRNA biogenesis, cancer related miRNAs, and miRNA therapeutics.

Keywords: cancer; microRNA; oncomir; therapeutics; tumor suppressor.

Publication types

  • Review

MeSH terms

  • Gene Expression Regulation, Neoplastic / drug effects
  • Gene Expression Regulation, Neoplastic / genetics
  • Humans
  • MicroRNAs / agonists
  • MicroRNAs / antagonists & inhibitors
  • MicroRNAs / biosynthesis
  • MicroRNAs / drug effects*
  • Molecular Targeted Therapy* / trends
  • Neoplasms / drug therapy*
  • Neoplasms / genetics*

Substances

  • MicroRNAs